TBC1D9

Across TCGA pan-cancer cohorts, TBC1D9 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D9 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TBC1D9 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TBC1D9 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where TBC1D9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	III,IV	0.329	0.995	.002	30	view →
PDAC	DFS	Quartile	All	0.672	0.227	.001	16	view →
CCRCC	OS	Quartile	III,IV	0.433	0.980	.036	7	view →
UCEC	DFS	Median	All	0.931	1.000	.021	6	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.353	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D9–LUAD (DFS)

Open the LUAD breakdown →